CN104610441B - 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 - Google Patents
用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 Download PDFInfo
- Publication number
- CN104610441B CN104610441B CN201510097025.2A CN201510097025A CN104610441B CN 104610441 B CN104610441 B CN 104610441B CN 201510097025 A CN201510097025 A CN 201510097025A CN 104610441 B CN104610441 B CN 104610441B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- gpc3
- antibody
- monophosphoinositideproteoglycans proteoglycans
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 102000010956 Glypican Human genes 0.000 title abstract description 9
- 108050001154 Glypican Proteins 0.000 title abstract description 9
- 108050007237 Glypican-3 Proteins 0.000 title abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 102000036639 antigens Human genes 0.000 claims abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 12
- 238000001262 western blot Methods 0.000 claims abstract description 10
- 238000011160 research Methods 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 35
- 201000007270 liver cancer Diseases 0.000 claims description 17
- 208000014018 liver neoplasm Diseases 0.000 claims description 17
- 206010003445 Ascites Diseases 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 238000011091 antibody purification Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 230000007910 cell fusion Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 13
- 238000010166 immunofluorescence Methods 0.000 abstract description 5
- 102100032530 Glypican-3 Human genes 0.000 description 35
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 35
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 1
- WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LPYPANUXJGFMGV-FXQIFTODSA-N Gln-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LPYPANUXJGFMGV-FXQIFTODSA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical class [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- RCLOWEZASFJFEX-KKUMJFAQSA-N Tyr-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RCLOWEZASFJFEX-KKUMJFAQSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- -1 acyl heparin sulfate Chemical compound 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 101150039713 gpc3 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明“用于制备磷脂酰肌醇蛋白聚糖‑3(GPC3)单抗的人工半抗原、制备方法及获得的单克隆抗体”,属于医学免疫检测技术,人工抗原其氨基酸序列如Seq ID No.1所示。本发明还提供了采用上述人工抗原制备磷脂酰肌醇蛋白聚糖‑3单抗的方法,以及制备而得的单抗及该单抗检测磷脂酰肌醇蛋白聚糖‑3的用途。根据本发明的方法筛选到的一株单抗,效价达到1:400000,特异性强。可用于于针对GPC3的免疫荧光和蛋白印迹(Western blotting)检测方法及科学研究。
Description
技术领域
本发明涉及医学免疫检测技术,特别是用于制备磷脂酰肌醇蛋白聚糖-3(GPC3)单抗的人工抗原、制备方法及获得的单克隆抗体。
背景技术
肝细胞癌(hepatocellular carcinoma,HCC)是目前全世界发病率很高的第五大癌症,我国每年死于肝癌约11万人,占全世界肝癌死亡人数的45%。目前外科手术切除肿瘤仍是治疗HCC最好、最快捷的方法。然而,大多数患者就诊时已失去了最佳治疗时机,能够早期手术切除者只占10-20%,即使手术切除,复发率仍很高。所以早期发现、早期诊断、早期治疗HCC是提高患者生存率的关键,也是预后和治疗的关键。
磷脂酰肌醇蛋白聚糖3(glypican-3,GPC3),其基因位于人染色体X26q1,长900kb,GPC3开放阅读框有1740bp,编码580个氨基酸,分子量为66kD。GPC3基因编码的蛋白属于硫酸已酰肝素蛋白聚糖(heparan sulfate proteoglycans,HSPGs),通过糖基磷脂酰蛋白(glycosyl-phosphatidylinositol anchor,CPI)锚定在细胞表面,可结合生长因子等,调控着细胞生长、繁殖、分化、黏附和迁移等行为。研究证实GPC3蛋白在肝癌组织中高表达,而在非癌组织中没有表达或表达极少,并能在血中检测到。用免疫组化的方法检测GPC3阳性者在80%以上。而其他良性肝病和正常肝组织中表达率为0,其特异度应在90%以上。另外,GPC3在对于小肝癌在血清中的检出率明显高于AFP,两者分别是56.3%和31.3%。因此,GPC3对HCC的诊断率明显高于AFP,尤其在AFP阴性的早期肝癌的诊断中发挥重要作用。
另外,GPC3对于肝癌而言或许不仅仅可以用于诊断,在肝癌的治疗方面也有所帮助。由于GPC3在肝癌中高度特异性的表达,因而可以将其作为一种肝癌免疫治疗的靶点,选择一种对GPC3有高度亲和力的载体,通过该载体将能杀伤癌细胞的物质如化疗药、放射性核素、毒蛋白等运送到肿瘤靶细胞,从而可以对该肿瘤靶细胞产生选择性的杀伤作用。
然而,目前市场上销售的商品化的GPC3抗体多为多克隆抗体,活性较低且试验结果很不稳定,直接影响到实验研究的深入开展及在肝癌治疗中的应用。
发明内容
本发明根据上述领域的空白和需求,提供用于制备磷脂酰肌醇蛋白聚糖-3(GPC3)单抗的人工抗原、制备方法及获得的单克隆抗体。
一种磷脂酰肌醇蛋白聚糖-3人工半抗原,其特征在于,其氨基酸序列如Seq IDNo.1所示。
所述的人工半抗原在制备磷脂酰肌醇蛋白聚糖-3单抗中的用途。
一种磷脂酰肌醇蛋白聚糖-3的单克隆抗体的制备方法,包括以下步骤:
(1)采用抗原免疫动物,
(2)细胞融合,
(3)单抗筛选,
(4)腹水制备和抗体纯化;
其特征在于,所述抗原为氨基酸序列如Seq ID No.1所示的多肽与匙孔血蓝蛋白偶联而得的偶联物。
一种磷脂酰肌醇蛋白聚糖-3的单克隆抗体,其特征在于,是采用所述的人工半抗原与匙孔血蓝蛋白偶联而得的偶联物为免疫原制备筛选而得。
所述的单克隆抗体,是保藏号为CGMCC No.10315的杂交瘤细胞所分泌。
一株分泌磷脂酰肌醇蛋白聚糖-3的单克隆抗体的杂交瘤细胞,保藏号为CGMCCNo.10315。
一种用于检测磷脂酰肌醇蛋白聚糖-3的免疫检测试剂盒,其特征在于包括捕捉抗体,所述捕捉抗体为所述的单克隆抗体。
一种用于检测磷脂酰肌醇蛋白聚糖-3的蛋白质印迹试剂盒,其特征在于,包括针对检测磷脂酰肌醇蛋白聚糖-3的探针,所述探针为所述的单克隆抗体。
上述的单克隆抗体在肝癌细胞研究中的用途。
本发明的发明思路基于下述三方面的考虑。第一,GPC3广泛表达于肝癌细胞表面,是肝癌早期诊断和靶向性治疗的主要的标靶;第二,市场上销售的商品化GPC3抗体多为多克隆抗体,并且效价极不稳定,直接影响到科学研究的深入开展及在肝癌治疗中的应用;第三,我们选择多个抗原表位进行多肽合成、动物免疫、杂交瘤融合及腹水制备等抗体制备方法结合实际的科研实验进行验证,从而大大提高抗体制备效率。
基于本发明的成果,本发明请求保护用于制备单抗的人工抗原,其氨基酸序列如Seq IDNo.1(选自来源于NP_004475.1的一段)所示。本发明还请求采用该人工抗原制备单抗的方法,以及获得的单抗,单抗的用途即采用该单抗的试剂盒。
本发明提供GPC3单克隆抗体,抗体特异性强,并且效价高,ELISA检测效价可达1:400000,因此试验中GPC3抗体使用浓度较低,抗体用量较少。
可用于针对GPC3抗原的免疫荧光和蛋白印迹(Western blotting)等科学研究。
生物保藏信息:
保藏号:CGMCC No.10315
保藏日期:2015年1月21日
保藏单位:中国微生物菌种保藏管理委员会普通微生物中心
保藏地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮政编码:100101
附图说明
图1.小鼠融合前血清ELISA检测结果曲线图
其中,横坐标为表1所示的8个不同的效价梯度,纵坐标为OD450值。
图2.免疫荧光方法中采用GPC3单克隆抗体检测肝癌细胞系HepG2细胞中GPC3
第一列为GPC3抗体免疫荧光(Cy3标记二抗)在肝癌细胞系HepG2细胞表面的显色,第二列为采用DAPI染细胞核,为蓝色(100×油镜下),第三列为第一列及第二列的合成图。图3.采用GPC3单克隆抗体的蛋白质印迹方法检测肝癌细胞中的GPC3。
其中,三株抗体都可在肝癌细胞系HepG2中表达,分子量约为70KD,β-actin为阳性对照,约45KD。
具体实施方式
实施例1.GPC3单克隆抗体制备
1.免疫原的制备
选取GPC3蛋白序列(来源于NP_004475.1)第528-543位氨基酸序列(SED IDNO.1YDLDVDDAPGNSQQAT)进行多肽合成作为人工半抗原。
多肽合成由艾比玛特生物医药(上海)有限公司合成并进行纯化。
纯化后的多肽分别与匙孔血蓝蛋白(KLH)和牛血清白蛋白(BSA)偶联,偶联反应按照美国Pierce公司的试剂盒(Imject Maleimide Activated Immunogen Conjugation KitWith mcKLH and BSA)操作说明书进行偶联后即刻过柱纯化、分装。
多肽-KLH偶联复合物用于免疫小鼠,多肽-BSA偶联复合物用于ELASA检测小鼠血清和杂交瘤细胞上清及腹水的抗体效价。
2.动物免疫
将合成的蛋白抗原多肽-KLH分别免疫鼠龄为6-8周的雌性BALB/C健康小鼠,第一次免疫用等量完全弗氏佐剂(CFA)充分乳化抗原,每只小鼠注射抗原量100ug/只,加强免疫两次,每次间隔两周,用等量不完全弗氏佐剂(IFA)乳化抗原。第二次和第三次免疫后10天取小鼠尾静脉血清检测抗体效价,根据结果决定是否再行加强免疫。挑选出三只体内抗体效价高的小鼠,选择免疫反应最好的小鼠脾脏进行融合。(见表1和图1)。
表1.小鼠融合前血清ELISA检测数据表
注:PC是阳性对照,NC是阴性对照。判断标准是:大于NC两倍且大于0.25的OD 450值对应的稀释度值即为该抗体的效价。
3.融合和单抗筛选
免疫反应最好的小鼠的脾细胞与骨髓瘤细胞(SP2/0)进行融合,融合后的细胞经过适当稀释,分置于96孔培养板中培养,培养10-14天进行ELISA检测,挑选OD值高的孔中的细胞进行有限稀释法亚克隆。
具体方法如下:将有限稀释的细胞培养至96孔板中,待克隆生长到全孔的1/6时,标记单克隆及多克隆,对单克隆进行ELISA检测。ELISA检测后将OD值最高的单克隆再有限稀释接入96孔板中如上法所述再次亚克隆,此过程重复数次,直至阳性孔比率为100%的为建株成功的细胞株。将筛选得到的阳性单克隆扩大培养,细胞数按1-2×106/管进行冻存。同时收集细胞安排腹水制备。
4.腹水制备
细胞株采用小鼠腹腔接种法制备腹水,10-14天收集腹水,ELISA检测腹水是否制备成功。
5.抗体纯化
采用蛋白G柱纯化腹水,纯化后抗体重新进行效价测定,显示出10株抗体效价大于1:400000(见表2)。
表2.抗体效价验证数据表
注:PC是阳性对照,NC是阴性对照。判断标准是:大于NC两倍且大于0.25的OD450值对应的稀释度值即为该抗体的效价。
其中,阳性对照是第三次免疫后小鼠血清,阴性对照是免疫前小鼠血清。
6.抗体验证
经过人和小鼠免疫荧光和Western blotting验证(实施例2和3),得知第1、8和9株抗体具有良好的特异性,可很好应用于上述科学实验中(见图2和图3)。
其中第1株抗体(PEG689)对应的单克隆细胞株,保藏号为:CGMCC No.10315。
实施例2.GPC3单克隆抗体在免疫荧光实验中的应用
用免疫荧光方法检测人肝癌细胞系HepG2细胞中的GPC3。
圆形盖玻片依次在100%丙酮中洗涤40min,无水乙醇中洗涤20min,0.1mol/L盐酸中洗涤40min,蒸馏水中洗涤10min,高压灭菌25min。盖玻片预先放入培养板孔中经由右旋多聚赖氨酸包被。每孔分别加培养液0.5mL(24孔板)、1mL(12孔板)和2mL(6孔板)。将HepG2细胞复苏后,将细胞接种到培养皿中。细胞接种浓度分别为每孔2.5×105个/孔(24孔板)、5.0×105个/孔(12孔板)和12×105个/孔(6孔板),置于37℃、体积分数为5%CO2恒湿培养箱温育,每3天更换1次培养液。
细胞培养第5天开始GPC3免疫荧光抗体检测,具体步骤如下:去细胞培养液,细胞依次经1×PBS清洗5min;4%多聚甲醛固定5min;1×PBS清洗5min;1×PBS清洗5min×2次;3%BSA+1%羊血清37℃封闭1h;实施例1选出的GPC3单克隆抗体(1:2500稀释)37℃温育1h或4℃过夜;1×PBS清洗10min×3次;Cy3标记抗小鼠二抗(1:1000稀释)37℃温育1h;1×PBS清洗20min 3次;4',6-二脒基-2-苯基吲哚(DAPI)封片后于正像荧光显微镜下阅片拍照(结果见图2)。
说明本发明的单抗可以稳定可靠地检测到人肝癌细胞系HepG2细胞中的GPC3。
实施例3.GPC3单克隆抗体在蛋白免疫印迹(Western blotting)中的应用
检测人肝癌细胞系HepG2细胞中的GPC3蛋白(western blotting法)
取培养好的人肝癌细胞系HepG2细胞,采用高盐裂解法提取细胞蛋白,具体步骤如下:用0.25%的胰酶将HepG2细胞消化,2000rpm,10分钟离心,去除培养基,加入500μl的1×PBS洗涤两遍,离心后,在冰上加入冰冷的2×的高盐裂解液(1%NP40,0.1%SDS,0.04%脱氧胆酸钠,150mM NaCl,50mM pH8.0Tris-HCl,5mM EDTA,用时加入1:1000PMSF),在冰上放置20分钟,使其充分裂解。4℃离心20分钟,取上清行蛋白定量。行PAGE电泳,每孔上样蛋白30μg,PVDF膜稳流100mA,4℃冰箱中转膜3小时;取出膜6%脱脂奶粉/PBS室温封闭2小时;1×PBS洗膜10分钟×3次;3%BSA(含1:1000叠氮钠)1:10000倍稀释的实施例1制备得到的GPC3单克隆抗体4℃杂交过夜(1:10000倍稀释的β-actin相同条件杂交作为阳性对照);1×PBS洗膜10分钟×3次;3%脱脂奶粉/PBS1:10000倍稀释的二抗室温杂交1小时。1×PBS洗膜10分钟×3次后暗室发光洗片(结果见图3)。
SEQUENCE LISTING
<110> 首都医科大学
<120> 用于制备磷脂酰肌醇蛋白聚糖-3(GPC3)单抗的人工半抗原、制备方法及获得的单克隆抗体
<130> P150100-YKD
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 16
<212> PRT
<213> GPC3人工半抗原D
<400> 1
Tyr Asp Leu Asp Val Asp Asp Ala Pro Gly Asn Ser Gln Gln Ala Thr
1 5 10 15
Claims (9)
1.一种磷脂酰肌醇蛋白聚糖-3人工半抗原,其特征在于,其氨基酸序列如Seq ID No.1所示。
2.权利要求1所述的人工半抗原在制备磷脂酰肌醇蛋白聚糖-3单抗中的用途。
3.一种磷脂酰肌醇蛋白聚糖-3的单克隆抗体的制备方法,包括以下步骤:
(1)采用抗原免疫动物,
(2)细胞融合,
(3)单抗筛选,
(4)腹水制备和抗体纯化;
其特征在于,所述抗原为氨基酸序列如Seq ID No.1所示的多肽与匙孔血蓝蛋白偶联而得的偶联物。
4.一种磷脂酰肌醇蛋白聚糖-3的单克隆抗体,其特征在于,是采用权利要求1所述的人工半抗原与匙孔血蓝蛋白偶联而得的偶联物为免疫原制备筛选而得。
5.根据权利要求4所述的单克隆抗体,是保藏号为CGMCC No.10315的杂交瘤细胞所分泌,效价达1:400000。
6.一株分泌磷脂酰肌醇蛋白聚糖-3的单克隆抗体的杂交瘤细胞,保藏号为CGMCCNo.10315,分泌的抗体的效价达1:400000。
7.一种用于检测磷脂酰肌醇蛋白聚糖-3的免疫检测试剂盒,其特征在于包括捕捉抗体,所述捕捉抗体为权利要求4或5所述的单克隆抗体。
8.一种用于检测磷脂酰肌醇蛋白聚糖-3的蛋白质印迹试剂盒,其特征在于,包括针对检测磷脂酰肌醇蛋白聚糖-3的探针,所述探针为权利要求4或5所述的单克隆抗体。
9.权利要求4或5所述的单克隆抗体在肝癌细胞研究中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510097025.2A CN104610441B (zh) | 2015-03-04 | 2015-03-04 | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510097025.2A CN104610441B (zh) | 2015-03-04 | 2015-03-04 | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104610441A CN104610441A (zh) | 2015-05-13 |
CN104610441B true CN104610441B (zh) | 2018-02-13 |
Family
ID=53145116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510097025.2A Expired - Fee Related CN104610441B (zh) | 2015-03-04 | 2015-03-04 | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104610441B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202134286A (zh) * | 2019-12-05 | 2021-09-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗gpc3抗體、其抗原結合片段及其醫藥用途 |
CN111175520A (zh) * | 2020-01-15 | 2020-05-19 | 河北省科学院生物研究所 | 一种Glypican-3双抗体夹心法检测试剂盒及检测方法 |
CN112608907B (zh) * | 2020-12-18 | 2023-01-17 | 十堰市太和医院(湖北医药学院附属医院) | 磷脂酰肌醇蛋白聚糖3单克隆抗体,杂交瘤细胞株和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1842540A (zh) * | 2004-07-09 | 2006-10-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
CN101287492A (zh) * | 2005-10-14 | 2008-10-15 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖-3抗体 |
CN101633693A (zh) * | 2009-08-24 | 2010-01-27 | 中国人民解放军第二军医大学 | 一种抗gpc3的单克隆抗体 |
CN102633864A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | 一种gpc3抗原多肽,抗gpc3的多克隆抗体及其应用 |
CN102634487A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | Gpc3单克隆抗体杂交瘤细胞株8g6及其制备方法和应用 |
CN102634486A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | Gpc3单克隆抗体杂交瘤细胞株7d11及其制备方法和应用 |
-
2015
- 2015-03-04 CN CN201510097025.2A patent/CN104610441B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1842540A (zh) * | 2004-07-09 | 2006-10-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
CN101287492A (zh) * | 2005-10-14 | 2008-10-15 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖-3抗体 |
CN101633693A (zh) * | 2009-08-24 | 2010-01-27 | 中国人民解放军第二军医大学 | 一种抗gpc3的单克隆抗体 |
CN102633864A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | 一种gpc3抗原多肽,抗gpc3的多克隆抗体及其应用 |
CN102634487A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | Gpc3单克隆抗体杂交瘤细胞株8g6及其制备方法和应用 |
CN102634486A (zh) * | 2012-03-28 | 2012-08-15 | 南方医科大学 | Gpc3单克隆抗体杂交瘤细胞株7d11及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104610441A (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103992988B (zh) | 一种杂交瘤细胞株及其产生的抗犬瘟热病病毒n蛋白的单克隆抗体 | |
CN110903389B (zh) | 抗gfap蛋白单克隆抗体、细胞系及其制备方法和应用 | |
CN104610441B (zh) | 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体 | |
US11459402B2 (en) | Hybridoma cell strain and monoclonal antibody produced therefrom against serine protease of Trichinella spiralis in intestinal stage and application thereof | |
CN102634486A (zh) | Gpc3单克隆抗体杂交瘤细胞株7d11及其制备方法和应用 | |
CN104894074B (zh) | 分泌s100a9单克隆抗体的杂交瘤细胞株、单克隆抗体及其应用 | |
CN102634487A (zh) | Gpc3单克隆抗体杂交瘤细胞株8g6及其制备方法和应用 | |
CN111234023B (zh) | 小细胞肺癌检测试剂盒 | |
CN102221615A (zh) | 一种基于Angiogenin检测的双抗夹心ELISA方法 | |
CN105017403B (zh) | 胰腺癌相关多肽dap44单克隆抗体的制备及其应用 | |
CN102776154A (zh) | 小鼠抗人β-Tubulin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN103173412B (zh) | 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN113832132A (zh) | 一种烙铁头svmp蛋白特异性短肽、抗烙铁头svmp蛋白抗体和蛇伤检测试剂盒 | |
CN103173417B (zh) | 小鼠抗人cea单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN105886475B (zh) | 一种dna依赖蛋白激酶的催化亚单位的单克隆抗体及应用 | |
WO2012079488A1 (zh) | 一种p28GANK单克隆抗体及其制备用多肽与应用 | |
CN108048406A (zh) | 小鼠抗人Thyroglobulin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN109970854B (zh) | 一种腐食酪螨Der p10单克隆抗体及其制备方法与应用 | |
CN107090439A (zh) | 一株分泌抗嗜铬素a单克隆抗体的杂交瘤细胞株及其应用 | |
AU2021104248A4 (en) | Recombinant Human VASN Protein-LRR Domain Protein and Monoclonal Antibody Thereof | |
CN110922485B (zh) | 抗Ep-cam蛋白单克隆抗体、细胞系及其制备方法和应用 | |
CN103173414B (zh) | 小鼠抗人p504s单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 | |
CN102115492B (zh) | 血管内皮生长因子受体部分多肽及其应用 | |
CN102127149B (zh) | 心肌特异性同源盒部分多肽及其应用 | |
CN111349170B (zh) | 免疫相关gtp酶家族m(irgm)的单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180213 Termination date: 20210304 |